PDF(Pubmed)
Abstract：
UNASSIGNED: The identification of new biomarkers in autosomal-dominant polycystic kidney disease (ADPKD) is crucial to improve and simplify prognostic assessment as a basis for patient selection for targeted therapies. Post hoc analyses of the TEMPO 3:4 study indicated that copeptin could be one of those biomarkers.
UNASSIGNED: Copeptin was tested in serum samples from patients of the AD(H)PKD study. Serum copeptin levels were measured using a time-resolved amplified cryptate emission (TRACE)-based assay. In total, we collected 711 values from 389 patients without tolvaptan treatment and a total of 243 values (of which 64 were pre-tolvaptan) from 94 patients on tolvaptan. These were associated with rapid progression and disease-causing gene variants and their predictive capacity tested and compared with the Mayo Classification.
UNASSIGNED: As expected, copeptin levels showed a significant negative correlation with estimated glomerular filtration rate (eGFR). Measurements on tolvaptan showed significantly higher copeptin levels (9.871 pmol/L vs 23.90 pmol/L at 90/30 mg; P < .0001) in all chronic kidney disease stages. Linear regression models (n = 133) show that copeptin is an independent predictor of eGFR slope. A clinical model (including eGFR, age, gender, copeptin) was nearly as good (R2 = 0.1196) as our optimal model (including height-adjusted total kidney volume, eGFR, copeptin, R2 = 0.1256). Adding copeptin to the Mayo model improved future eGFR estimation.
UNASSIGNED: Copeptin levels are associated with kidney function and independently explained future eGFR slopes. As expected, treatment with tolvaptan strongly increases copeptin levels.
UNASSIGNED: Copeptin was tested in serum samples from patients of the AD(H)PKD study. Serum copeptin levels were measured using a time-resolved amplified cryptate emission (TRACE)-based assay. In total, we collected 711 values from 389 patients without tolvaptan treatment and a total of 243 values (of which 64 were pre-tolvaptan) from 94 patients on tolvaptan. These were associated with rapid progression and disease-causing gene variants and their predictive capacity tested and compared with the Mayo Classification.
UNASSIGNED: As expected, copeptin levels showed a significant negative correlation with estimated glomerular filtration rate (eGFR). Measurements on tolvaptan showed significantly higher copeptin levels (9.871 pmol/L vs 23.90 pmol/L at 90/30 mg; P < .0001) in all chronic kidney disease stages. Linear regression models (n = 133) show that copeptin is an independent predictor of eGFR slope. A clinical model (including eGFR, age, gender, copeptin) was nearly as good (R2 = 0.1196) as our optimal model (including height-adjusted total kidney volume, eGFR, copeptin, R2 = 0.1256). Adding copeptin to the Mayo model improved future eGFR estimation.
UNASSIGNED: Copeptin levels are associated with kidney function and independently explained future eGFR slopes. As expected, treatment with tolvaptan strongly increases copeptin levels.
摘要：
■在常染色体显性多囊肾病（ADPKD）中鉴定新的生物标志物对于改善和简化预后评估至关重要，作为患者选择靶向治疗的基础。TEMPO3:4研究的事后分析表明，和肽素可能是这些生物标志物之一。
■在来自AD(H)PKD研究的患者的血清样品中测试和肽素。使用基于时间分辨的扩增隐窝酸发射(TRACE)的测定来测量血清和肽素水平。总的来说,我们从未接受托伐普坦治疗的389例患者中收集了711个值,从接受托伐普坦治疗的94例患者中收集了243个值(其中64个为托伐普坦治疗前).这些与快速进展和致病基因变异有关，并与Mayo分类进行了测试和比较。
■如预期的那样，和肽素水平与估计的肾小球滤过率（eGFR）呈显着负相关。托伐普坦的测量显示，在所有慢性肾脏疾病阶段，和肽素水平均显着较高（9.871pmol/Lvs23.90pmol/L，90/30mg；P<0.0001）。线性回归模型(n=133)显示和肽素是eGFR斜率的独立预测因子。临床模型(包括eGFR，年龄,性别,copeptin）几乎与我们的最佳模型一样好（R2=0.1196）（包括高度调整后的总肾脏体积，eGFR,copeptin,R2=0.1256)。将copeptin添加到Mayo模型中改进了未来的eGFR估计。
■和肽素水平与肾功能相关，并独立解释未来的eGFR斜率。不出所料,托伐普坦治疗可显著增加和肽素水平。
■在来自AD(H)PKD研究的患者的血清样品中测试和肽素。使用基于时间分辨的扩增隐窝酸发射(TRACE)的测定来测量血清和肽素水平。总的来说,我们从未接受托伐普坦治疗的389例患者中收集了711个值,从接受托伐普坦治疗的94例患者中收集了243个值(其中64个为托伐普坦治疗前).这些与快速进展和致病基因变异有关，并与Mayo分类进行了测试和比较。
■如预期的那样，和肽素水平与估计的肾小球滤过率（eGFR）呈显着负相关。托伐普坦的测量显示，在所有慢性肾脏疾病阶段，和肽素水平均显着较高（9.871pmol/Lvs23.90pmol/L，90/30mg；P<0.0001）。线性回归模型(n=133)显示和肽素是eGFR斜率的独立预测因子。临床模型(包括eGFR，年龄,性别,copeptin）几乎与我们的最佳模型一样好（R2=0.1196）（包括高度调整后的总肾脏体积，eGFR,copeptin,R2=0.1256)。将copeptin添加到Mayo模型中改进了未来的eGFR估计。
■和肽素水平与肾功能相关，并独立解释未来的eGFR斜率。不出所料,托伐普坦治疗可显著增加和肽素水平。
